Please login to the form below

Not currently logged in
Email:
Password:

Eduardo Bravo becomes head of EBE

TiGenix CEO appointed president of the EBE’s board of directors

The European Biopharmaceutical Enterprises (EBE) has appointed Eduardo Bravo as president of its board of directors for the 2016-2018 term.

Bravo graduates to the leadership role of the European trade association from his previous position as its vice president.

He said: “This is a very exciting time at the EBE. We are well positioned to help new initiatives and cutting-edge technologies advance biopharmaceutical pipelines toward eventual solutions for difficult-to-treat conditions and diseases.

“It is a pleasure to be working with such a dedicated group of senior industry leaders to support emerging sciences in the search of therapeutic solutions.”

Bravo has over 25 years of experience in the biopharmaceutical industry, and is a member of the executive committee of the Alliance for Regenerative Medicine (ARM).

He currently serves as chief executive officer of TiGenix, a biopharma company based in Belgium, and prior to this served as Cellerix's chief executive officer between 2006 and 2011.

Barbara Freischem, EBE's executive director, said: “Mr Bravo brings so much to our organisation. 

“Coming from the field of advanced therapies, he helps bridge the gap between the lab and personalised medicines within a thriving and innovative ecosystem.”

28th June 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics